Summary of Key Information:

Reporting Period (Quarter/Year): Quarter ended June 30, 2026 (Q1 FY27)

Nature of Filing / Announcement: Outcome of Board Meeting pursuant to Regulation 30 and 33 of SEBI Listing Regulations

Audit Opinion:

The limited review reports by the Statutory Auditors, M S K A & Associates LLP, for both standalone and consolidated unaudited financial results did not contain any modifications or qualifications. The auditors concluded that nothing came to their attention causing them to believe the statements contained any material misstatement.

Key Financial Highlights [Amounts in ₹ lakhs]:

Consolidated Results for Quarter Ended June 30, 2026:

  • Revenue from Operations: ₹6,415.77 lakhs (compared to ₹7,762.50 lakhs in Q1 FY26 - down 17.3% YoY)
  • Other Income: ₹849.17 lakhs
  • Total Income: ₹6,500.69 lakhs
  • Total Expenses: ₹4,522.22 lakhs
  • Profit Before Tax: ₹1,978.47 lakhs
  • Current Tax: ₹508.80 lakhs
  • Deferred Tax Credit: ₹(70.64) lakhs
  • Net Profit: ₹1,476.73 lakhs
  • Total Comprehensive Income: ₹1,475.84 lakhs
  • EPS (Basic & Diluted): ₹114.86

Standalone Results for Quarter Ended June 30, 2026:

  • Revenue from Operations: ₹6,415.77 lakhs
  • Other Income: ₹849.17 lakhs
  • Total Income: ₹6,500.69 lakhs
  • Total Expenses: ₹4,525.33 lakhs
  • Profit Before Tax: ₹1,975.36 lakhs
  • Current Tax: ₹508.80 lakhs
  • Deferred Tax Credit: ₹(70.64) lakhs
  • Net Profit: ₹1,473.62 lakhs
  • Total Comprehensive Income: ₹1,473.62 lakhs
  • EPS (Basic & Diluted): ₹114.86

Comparison with Previous Periods:

The consolidated financial results show a significant decrease in revenue from operations compared to the same quarter last year (₹7,762.50 lakhs in Q1 FY26) but an improvement in net profit (₹1,390.00 lakhs in Q1 FY26).

Segment-wise Performance:

The Group has only one reportable segment: "manufacture of active pharmaceutical ingredients and allied services."

Geography-wise Revenue from External Customers:

  • India: ₹832.64 lakhs
  • Europe: ₹3,034.58 lakhs
  • USA and North America: ₹1,996.37 lakhs
  • Rest of the World: ₹551.82 lakhs
  • Total Revenue from Operations: ₹6,415.77 lakhs

Non-current Assets by Geography (excluding financial assets):

  • India: ₹1,52,457.60 lakhs
  • Rest of the World: ₹2.51 lakhs
  • Total: ₹1,52,460.11 lakhs

Corporate Actions:

Corporate Guarantee:

  • The Board approved execution of a deed of Corporate Guarantee for ₹40 crores in favor of Gland Pharma Limited
  • This guarantee secures the company's obligations under a Loan Licence Agreement to be entered with Gland Pharma
  • The guarantee is irrevocable and unconditional, continuing until obligations are fulfilled
  • No promoter/promoter group has any interest in this transaction

Capacity Enhancement:

  • The Board approved enhancement of manufacturing capacity at Unit 1 located at Bonthapally Village, Gummadidala Mandal, Sangareddy District, Telangana
  • Proposed additional capacity: 18 KL
  • Implementation period: 6-7 months
  • Estimated capital outlay (including GST): ₹39.8 crores
  • Mode of financing: Through internal accruals
  • Rationale: To maintain and cater to the growing demands of customers

Other Significant Information:

Strategic Partnership with Gland Pharma:

  • Long-term strategic partnership to establish a sterile manufacturing suite for Active Pharmaceutical Ingredients (APIs) pertaining to microparticle depot products
  • Gland Pharma will expand its existing sterile manufacturing infrastructure through an additional dedicated suite at its JNPC facility in Visakhapatnam
  • The facility will be constructed and operated to cGMP, USFDA and EU standards
  • The suite will add approximately 1,400 kg of annual capacity
  • The partnership aims to provide an integrated CDMO solution encompassing development, scale-up, regulatory support and commercial manufacturing of sterile APIs